← FDA DRUG APPROVALS

FDA ANDA · ANDA078030

STAVUDINE

Sponsor: CIPLA LTD

APPLICATION
ANDA078030
TYPE
ANDA
ORIGINAL APPROVAL
2009-03-20
LATEST ACTION
2020-02-10
ROUTE
ORAL
DOSAGE FORM
FOR SOLUTION
MARKETING STATUS
Discontinued

Products

STAVUDINEDiscontinued
STAVUDINE 1MG/ML · FOR SOLUTION · ORAL

Approval history

2020-02-10Labeling · Supplement 7 · standardAP
2020-02-10Labeling · Supplement 6 · standardAP
2016-02-16Labeling · Supplement 4AP
2011-11-08Labeling · Supplement 3AP
2009-09-23Labeling · Supplement 1AP
2009-03-20OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →